(HealthDay)—For patients with intracerebral hemorrhage, those who start antiplatelet therapy do not have an increased risk for recurrence, including those with cerebral microbleeds, according to two studies published online May 22 in The Lancet and The Lancet Neurology. Rustam Al-Shahi Salman, Ph.D., from the Usher Institute of Population Health Sciences and Informatics at the University